China National Pharmaceutical Group Corporation (Sinopharm) is the largest medical and healthcare group under the direct leadership of the State-owned Assets Supervision and Administration Commission of the State Council.It is famous for its most comprehensive competitiveness and complete chain of the whole pharmaceutical industry in China.
Sinopharm has 11 wholly-owned or share-holding subsidiaries and 6 listed companies, covering every aspect of medical and healthcare industry. In R&D sector, Sinopharm has 2 academicians of Chinese Academy of Engineering, 7 national level research institutes and a large number of outstanding researchers.
It is the front runner in China for R&D of chemical drugs and biological products. In manufacturing sector, Sinopharm has built up a manufacturing base for a whole industrial chain from biological products, chemical drugs to modern TCM. The annual sales revenue exceeds RMB 10 billion. In terms of production volume, Sinopharm ranks No.4 in the world for its biological products.
In circulation sector, Sinopharm has a medical distribution network system of 30 distribution centers up to international standards and nearly 2,000 retail outlets to cover 31 provinces, autonomous regions and municipalities in China. As a leading provider of supply chain services, it is the biggest retailer of medicine, healthcare products and medical equipments. In engineering design sector, the engineering design institutes of Sinopharm enjoy a high reputation and create a great influence in China. They have edited and compiled more than 10 national standards of the industry and completed more than 400 pharmaceutical engineering designs. Sinopharm tops the list in China’s pharmaceutical project design.